Rare Gastrointestinal Diseases Treatment Global Market Report 2025

Description

Rare gastrointestinal (GI) diseases treatment refers to specialized medical care, therapies, and interventions aimed at managing uncommon digestive system disorders that affect a small segment of the population. Its primary purpose is to alleviate symptoms, prevent complications, improve quality of life, and, when possible, achieve long-term disease control or remission.

The primary types of rare gastrointestinal diseases treatment include drugs and devices. Drugs are substances used to prevent, treat, or manage diseases and medical conditions, including specialized therapies such as biologics and small molecules. They target specific symptoms, reduce inflammation, and improve overall patient health and quality of life. These treatments can be administered via various routes, including oral, intravenous (IV), subcutaneous, and others. Applications include eosinophilic gastroenteritis, Hirschsprung's disease, and chronic intestinal pseudo-obstruction. End users include hospitals, research institutes, and other healthcare providers.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The rare gastrointestinal diseases treatment market research report is one of a series of new reports from The Business Research Company that provides rare gastrointestinal diseases treatment market statistics, including rare gastrointestinal diseases treatment industry global market size, regional shares, competitors with the rare gastrointestinal diseases treatment market share, rare gastrointestinal diseases treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the rare gastrointestinal diseases treatment industry. This rare gastrointestinal diseases treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rare gastrointestinal diseases treatment market size has grown strongly in recent years. It will grow from $1.36 billion in 2024 to $1.45 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth during the historic period is linked to increasing patient advocacy initiatives, a rising number of clinical trials for rare gastrointestinal (GI) therapies, greater early diagnosis through advanced screening, expanding collaboration between pharmaceutical companies and research institutes, and growing demand for targeted treatment options.

The rare gastrointestinal diseases treatment market size is expected to see strong growth in the next few years. It will grow to $1.81 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth projected for the forecast period is driven by increasing investment in novel drug development, rising adoption of personalized medicine, expansion of precision medicine, enhanced awareness and education among healthcare providers, and growth of rare disease patient registries. Primary trends during the forecast period include advancements in genomic and molecular diagnostics, development of targeted biologic therapies, innovations in drug delivery systems, progress in telehealth and remote patient monitoring, and development of AI-driven clinical decision support tools.

The increasing use of diagnostic testing is expected to drive growth in the rare gastrointestinal diseases treatment market in the coming years. Diagnostic tests are medical procedures performed to detect, diagnose, or monitor diseases, conditions, or infections in patients. Growing awareness about the importance of early disease detection is fueling demand for these tests, as timely diagnosis allows for prompt intervention and improved patient outcomes. Diagnostic testing plays a crucial role in treating rare gastrointestinal diseases by enabling early and accurate identification of the underlying conditions. It helps pinpoint specific disease pathways, supports personalized treatment planning, and improves overall patient care through timely medical responses. For example, in December 2024, the UK's National Health Service reported that the number of diagnostic tests conducted reached 2,544,809, up from 2,312,030 in 2023. This rise in diagnostic testing is therefore driving the market for rare gastrointestinal disease treatments.

Leading companies in this market are developing innovative therapies such as fully human monoclonal antibodies that target disease pathways to enhance patient outcomes. These antibodies are lab-engineered proteins derived entirely from human sources, designed to precisely target molecules responsible for disease, improving treatment effectiveness while minimizing side effects. For instance, in August 2023, Regeneron Pharmaceuticals, a US biotechnology firm, gained FDA approval for Veopoz (pozelimab-bbfg), a treatment for CHAPLE disease-a rare, hereditary gastrointestinal disorder. Veopoz is a fully human monoclonal antibody that targets complement factor C5 to regulate the overactive complement system responsible for protein loss and gastrointestinal damage in CHAPLE patients. This targeted approach addresses the root cause of the disease, preventing severe symptoms and potentially life-threatening complications.

In May 2023, Ironwood Pharmaceuticals, a US-based company specializing in gastrointestinal healthcare, acquired VectivBio Holding AG, a Switzerland-based clinical-stage biotechnology firm, for about $1 billion. Through this acquisition, Ironwood aims to broaden its gastrointestinal product portfolio by adding VectivBio's late-stage drug candidate, apraglutide, which is being developed to treat short bowel syndrome with intestinal failure. The deal leverages Ironwood's commercial and clinical expertise to accelerate growth, introduce innovative therapies, and enhance long-term shareholder value.

Major players in the rare gastrointestinal diseases treatment market are Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Bayer AG, Sanofi S.A., Zealand Pharma A/S, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Ipsen S.A., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Orphalan S.A., and Ellodi Pharmaceuticals Inc.

North America was the largest region in the rare gastrointestinal diseases treatment market in 2024. The regions covered in rare gastrointestinal diseases treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rare gastrointestinal diseases treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rare gastrointestinal diseases treatment market consists of revenues earned by entities by providing services such as diagnosis of rare gastrointestinal disorders, prescription of specialized therapies and medications, management and monitoring of patient treatment plans, and support programs for patients with rare digestive conditions. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare gastrointestinal diseases treatment market also includes sales of specialized drugs, biologics, nutritional therapies, and diagnostic kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rare Gastrointestinal Diseases Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rare gastrointestinal diseases treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rare gastrointestinal diseases treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rare gastrointestinal diseases treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Drugs; Device
2) By Route Of Administration: Oral; Intravenous (IV) Or Injectable; Subcutaneous; Other Routes Of Administration
3) By Application: Eosinophilic Gastroenteritis; Hercksprung's Disease; Chronic Intestinal Pseudo-Obstruction
4) By End User: Hospitals; Research Institutes; Other End Users
Subsegments:
1) By Drugs: Anti-Inflammatory Drugs; Immunosuppressive Agents; Biologic Therapies; Antibiotics; Proton Pump Inhibitors; Corticosteroids; Enzyme Replacement Therapies
2) By Devices: Endoscopic Devices; Diagnostic Imaging Systems; Surgical Instruments; Feeding Tubes; Stent Devices; Biopsy Devices
Companies Mentioned: Johnson & Johnson; Merck & Co. Inc.; Pfizer Inc.; Bayer AG; Sanofi S.A.; Zealand Pharma A/S; Novartis AG; AstraZeneca plc; GlaxoSmithKline plc; Eli Lilly and Company; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; Regeneron Pharmaceuticals Inc.; Ipsen S.A.; PTC Therapeutics Inc.; Ironwood Pharmaceuticals Inc.; Mirum Pharmaceuticals Inc.; Albireo Pharma Inc.; Orphalan S.A.; Ellodi Pharmaceuticals Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r38623

1. Executive Summary

2. Rare Gastrointestinal Diseases Treatment Market Characteristics

3. Rare Gastrointestinal Diseases Treatment Market Trends And Strategies

4. Rare Gastrointestinal Diseases Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Rare Gastrointestinal Diseases Treatment Growth Analysis And Strategic Analysis Framework

5.1. Global Rare Gastrointestinal Diseases Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Rare Gastrointestinal Diseases Treatment Market Growth Rate Analysis
5.4. Global Rare Gastrointestinal Diseases Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Rare Gastrointestinal Diseases Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Rare Gastrointestinal Diseases Treatment Total Addressable Market (TAM)

6. Rare Gastrointestinal Diseases Treatment Market Segmentation

6.1. Global Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Drugs
Device
6.2. Global Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous (IV) Or Injectable
Subcutaneous
Other Routes Of Administration
6.3. Global Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Eosinophilic Gastroenteritis
Hercksprung's Disease
Chronic Intestinal Pseudo-Obstruction
6.4. Global Rare Gastrointestinal Diseases Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Research Institutes
Other End Users
6.5. Global Rare Gastrointestinal Diseases Treatment Market, Sub-Segmentation Of Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Anti-Inflammatory Drugs
Immunosuppressive Agents
Biologic Therapies
Antibiotics
Proton Pump Inhibitors
Corticosteroids
Enzyme Replacement Therapies
6.6. Global Rare Gastrointestinal Diseases Treatment Market, Sub-Segmentation Of Device, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Endoscopic Devices
Diagnostic Imaging Systems
Surgical Instruments
Feeding Tubes
Stent Devices
Biopsy Devices

7. Rare Gastrointestinal Diseases Treatment Market Regional And Country Analysis

7.1. Global Rare Gastrointestinal Diseases Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Rare Gastrointestinal Diseases Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rare Gastrointestinal Diseases Treatment Market

8.1. Asia-Pacific Rare Gastrointestinal Diseases Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rare Gastrointestinal Diseases Treatment Market

9.1. China Rare Gastrointestinal Diseases Treatment Market Overview
9.2. China Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rare Gastrointestinal Diseases Treatment Market

10.1. India Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rare Gastrointestinal Diseases Treatment Market

11.1. Japan Rare Gastrointestinal Diseases Treatment Market Overview
11.2. Japan Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rare Gastrointestinal Diseases Treatment Market

12.1. Australia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rare Gastrointestinal Diseases Treatment Market

13.1. Indonesia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rare Gastrointestinal Diseases Treatment Market

14.1. South Korea Rare Gastrointestinal Diseases Treatment Market Overview
14.2. South Korea Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rare Gastrointestinal Diseases Treatment Market

15.1. Western Europe Rare Gastrointestinal Diseases Treatment Market Overview
15.2. Western Europe Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rare Gastrointestinal Diseases Treatment Market

16.1. UK Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rare Gastrointestinal Diseases Treatment Market

17.1. Germany Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rare Gastrointestinal Diseases Treatment Market

18.1. France Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rare Gastrointestinal Diseases Treatment Market

19.1. Italy Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rare Gastrointestinal Diseases Treatment Market

20.1. Spain Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rare Gastrointestinal Diseases Treatment Market

21.1. Eastern Europe Rare Gastrointestinal Diseases Treatment Market Overview
21.2. Eastern Europe Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rare Gastrointestinal Diseases Treatment Market

22.1. Russia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rare Gastrointestinal Diseases Treatment Market

23.1. North America Rare Gastrointestinal Diseases Treatment Market Overview
23.2. North America Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rare Gastrointestinal Diseases Treatment Market

24.1. USA Rare Gastrointestinal Diseases Treatment Market Overview
24.2. USA Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rare Gastrointestinal Diseases Treatment Market

25.1. Canada Rare Gastrointestinal Diseases Treatment Market Overview
25.2. Canada Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rare Gastrointestinal Diseases Treatment Market

26.1. South America Rare Gastrointestinal Diseases Treatment Market Overview
26.2. South America Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rare Gastrointestinal Diseases Treatment Market

27.1. Brazil Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rare Gastrointestinal Diseases Treatment Market

28.1. Middle East Rare Gastrointestinal Diseases Treatment Market Overview
28.2. Middle East Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rare Gastrointestinal Diseases Treatment Market

29.1. Africa Rare Gastrointestinal Diseases Treatment Market Overview
29.2. Africa Rare Gastrointestinal Diseases Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Rare Gastrointestinal Diseases Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Rare Gastrointestinal Diseases Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rare Gastrointestinal Diseases Treatment Market Competitive Landscape And Company Profiles

30.1. Rare Gastrointestinal Diseases Treatment Market Competitive Landscape
30.2. Rare Gastrointestinal Diseases Treatment Market Company Profiles
- 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Rare Gastrointestinal Diseases Treatment Market Other Major And Innovative Companies

31.1. Zealand Pharma A/S
31.2. Novartis AG
31.3. AstraZeneca plc
31.4. GlaxoSmithKline plc
31.5. Eli Lilly and Company
31.6. Takeda Pharmaceutical Company Limited
31.7. Teva Pharmaceutical Industries Ltd.
31.8. Regeneron Pharmaceuticals Inc.
31.9. Ipsen S.A.
31.10. PTC Therapeutics Inc.
31.11. Ironwood Pharmaceuticals Inc.
31.12. Mirum Pharmaceuticals Inc.
31.13. Albireo Pharma Inc.
31.14. Orphalan S.A.
31.15. Ellodi Pharmaceuticals Inc.

32. Global Rare Gastrointestinal Diseases Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rare Gastrointestinal Diseases Treatment Market

34. Recent Developments In The Rare Gastrointestinal Diseases Treatment Market

35. Rare Gastrointestinal Diseases Treatment Market High Potential Countries, Segments and Strategies

35.1 Rare Gastrointestinal Diseases Treatment Market In 2029 - Countries Offering Most New Opportunities
35.2 Rare Gastrointestinal Diseases Treatment Market In 2029 - Segments Offering Most New Opportunities
35.3 Rare Gastrointestinal Diseases Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer